Chugai Pharmaceutical Co.
 | |
| Public (K.K) | |
| Traded as | TYO: 4519 |
| Industry | Pharmaceutical Industry, Business import, production and development of drugs for medical sales |
| Founded | 1943 March 8 |
| Headquarters | Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo) |
Key people | Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO |
| Revenue | 72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007) |
| Website | www |
Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社 Chūgai Seiyaku Kabushikigaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.
History[edit]
- 1961 developed patents for synthesis of vitamin A
- 1995 acute promyelocytic sphere of drug treatment leukemia Vesanoid was released.
- 1996 anti-viral chemotherapeutic agent Hivid released (HIV reverse transcriptase inhibitor)
- 1997 – HIV protease inhibitor Invirase released
- 1999 – immunosuppressive agent Cellcept released
- 2000 – Release of an antiemetic drug Kytril, developed to combat the side effects of chemotherapy
- 2001 – Produced an anti-influenza virus Tamiflu (Roche)
- 2011 - Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
- 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[2]
Other notable developments[edit]
Scientists at Chugai discovered an erythromycin-derived motilin agonist called mitemcinal (GM-611 or 3′-N-dimethyl-11-deoxy-3′-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin). Mitemcinal was believed to have strong prokinetic properties, like its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as gastroparesis. If mitemcinal can be shown to be as effective a prokinetic agent, it would represent an advance in the field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.
See also[edit]
References[edit]
- ^ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
- ^ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 2016-06-11.
External links[edit]
 |
Wikimedia Commons has media related to Chugai Pharmaceutical. |
- English version of company homepage: Chugai Pharmaceutical Co., Ltd.
- The transfer of operations of the Company [1]
Authority control  |
|
|---|
 | This article about a Japanese corporation– or company–related topic is a stub. You can help Wikipedia by expanding it. |
